30 June 2008: Reference is made to the attached joint press release with Institute Pasteur de Lille. NorDiag has through its subsidiary Genpoint granted Institute Pasteur de Lille a license regarding use of one of NorDiag`s unique technologies to detect micro organisms in water, sludge and environment. The license covers France and some European countries.

- Part of our strategy is to generate revenues through expanding the use of our technologies outside our core field of human disease. We are extremely pleased to license the technology to Institute Pasteur de Lille which is a major player in the field of environment and health,  and ideally positioned to support our development, said CEO
Mårten Wigstøl.

Contact: CEO Mårten Wigstøl               Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of
colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Link to notice in Norwegian